The UK has become the first country to approve a COVID vaccine that targets both the original strain and the Omicron variant.
The Moderna jab was given the green light by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to meet the UK regulator’s standards of safety, quality and effectiveness.
The booster dose, known as “Spikevax bivalent Original/Omicron”, contains 25 micrograms of Omicron vaccine and 25 micrograms of original coronavirus vaccine.
A vaccine that works for two infections is known as bivalent.
Dr June Raine, chief executive of the MHRA, said: “I am pleased to announce the approval of the Moderna bivalent booster vaccine, which was found in the clinical trial to provide a strong immune response against the Omicron BA.1 variant as well as the original 2020 strain.
“The first generation of COVID-19 vaccines being used in the UK continue to provide important protection against the disease and save lives. What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve.”